KRIBIOLISA™ Davalintide ELISA

1 - 1000 ng/ml

Colorimetric, 450nm

Immunoassay for quantitative determination of Insulin Glargine in human serum and plasma Insulin Glargine is produced by recombinant DNA technology. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginine to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms micro- precipitates at physiological pH 7.4. Small amounts of insulin Glargine are slowly released from micro-precipitates giving the drug a long duration of action (up to 24 hours) and no pronounced peak concentration. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The method employs the quantitative sandwich enzyme immunoassay technique. In the first step, samples and standards are pipetted into microwells. If insulin Glargine is present in the samples or standards, it will form complex with Anti-insulin Glargine antibody, which is pre-coated onto microwells. In the second step, anti-Insulin Glargine HRP conjugate is pipetted and incubated. Free HRP conjugate will be removed by a washing step. In the third step, TMB substrate is added to microwells and color develops proportionally to the amount of Insulin Glargine present in the samples or standards. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Human serum, plasma and tissue extracts

1 ng/ml